Start up. Grow up. Succeed.

News 2008

Artificial Technology GmbH: Official Launch of EKI One Version 1.0

This news is bound to excite gamers and developers alike: EKI One Version 1.0 is now commercially available!

SuppreMol GmbH: SuppreMol GmbH Announces Expansion of its Management Team and Board Changes

SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced the expansion of its management team

Revotar Biopharmaceutical AG: Revotar closes 5.3 million EUR Series A financing round

Revotar Biopharmaceuticals AG today announced the successful closing of its Series A financing round of 5.3 million EUR.

Corimmun GmbH: Corimmun GmbH closes a EUR 5million financing round with MIG AG as lead investor

The biotech company Corimmun GmbH has successfully closed a series A financing with EUR 5 million.

Cenix BioScience GmbH: Cenix BioScience Signs Research Agreement with Regulus Therapeutics for miRNA-Targeted Drug Discovery

Cenix BioScience GmbH (Dresden), a leading specialist in advanced RNA interference (RNAi)-based research services today announced that they have signed a research agreement with Regulus Therapeutics LLC to advance the latter’s efforts in the discovery of novel therapeutic miRNA modulators.

Cenix BioScience GmbH: Following success of pilot, Cenix BioScience takes on second RNAi-Based Target Validation project for CellCentric

Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that it has initiated a second target validation project under the framework research agreement signed previously with UK-based CellCentric Ltd, a biotechnology company developing therapeutics against a series of novel epigenetic targets.

Artificial Technology GmbH

Artificial Technology GmbH brings with new "EKI One" middleware intelligence into play Computer and video games are already captivating with their realistic graphical style.

Revotar Biopharmaceuticals meets primary endpoint in Phase II COPD Study with inhaled Bimosiamose

Revotar Biopharmaceuticals AG today announced positive top-line results on a multi-center Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic obstructive pulmonary disease (COPD).

Revotar AG: Revotar Biopharmaceutical AG reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream

Revotar reports positive Phase I data in psoriasis with its Bimosiamose 5% Cream. Revotar Biopharmaceuticals AG today announced data from a Phase I study demonstrating that the topical application of its Bimosiamose 5% Cream in patients with plaque psoriasis has been safe and well tolerated.